Progyny Inc (PGNY) valuation
Progyny P/E ratio history
Progyny trades at 31.7 times its earnings over the last twelve months and 13.3 times the earnings analysts expect over the next twelve. At its last 6 fiscal year ends its P/E ranged from 30.3 (year to Dec 2024) to 103.8 (year to Dec 2022), with a median of 68.1.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $25.68 | $0.65 | 39.5 | — |
| Dec 31, 2024 | $17.25 | $0.57 | 30.3 | 29.1 |
| Dec 31, 2023 | $37.18 | $0.62 | 60.0 | 54.8 |
| Dec 31, 2022 | $31.15 | $0.30 | 103.8 | 87.4 |
| Dec 31, 2021 | $50.35 | $0.66 | 76.3 | — |
| Dec 31, 2020 | $42.39 | $0.47 | 90.2 | — |
| Dec 31, 2019 | $27.45 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Progyny valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| ProgynyPGNY | $2.29B | 31.7 | 13.3 | 1.7 |
| Arcus BiosciencesRCUS | $2.29B | — | — | 19.6 |
| Transmedics GroupTMDX | $2.28B | 17.1 | 35.1 | 3.4 |
| BiohavenBHVN | $2.32B | — | — | — |
| Prestige Consumer HealthcarePBH | $2.32B | 13.7 | 10.4 | 2.1 |
| Harmony Biosciences HldgHRMY | $2.24B | 12.6 | 6.3 | 2.3 |
| NeogenomicsNEO | $2.23B | — | 58.8 | 2.8 |
| Addus HomecareADUS | $2.34B | 22.0 | 17.2 | 1.6 |
| Clover Health Investments Corp ClaCLOV | $2.35B | — | 30.8 | 1.0 |
| Peer median | 15.4 | 24.0 | 2.3 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: PGNY financials · PGNY returns
No forecast, no recommendation. This page describes Progyny Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.